Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Jakavi (ruxolintib)
pCPA File Number:
22021
Negotiation Status:
Concluded with an LOI
Indication(s):
acute graft-versus-host disease
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
SR0688
pCPA Engagement Letter Issued:
2023-02-06
Negotiation Process Concluded:
2023-05-05